Athersys

Entity > Corporation > US > New York City New York > Athersys

About Athersys

Athersys, Inc. is an international biotechnology company that is focused in the field of regenerative medicine. They are committed to developing therapeutic products that they believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.

Athersys is Developing the MultiStem Cell Therapy: MultiStem cell therapy, a patented and proprietary allogeneic “off-the-shelf” stem cell product, is our lead platform product and has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is currently being evaluated in several clinical-stage programs.

Athersys' Business Strategy: Their principal business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and where they believe there is a substantial commercial opportunity.

Founding: Athersys was founded in 1995. They are headquartered in Cleveland, Ohio.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Athersys

Company Attribute Value
Address StreetAddress: 3201 Carnegie Ave, AddressLocality: Cleveland, AddressRegion: Ohio, PostalCode: 44115, AddressCountry: United States
Founding Date 1995
Name Athersys
Number Of Employees 104
Revenue $8,426,000 USD
Ticker Symbol NASDAQ: ATHX
Url athersys
Facebook facebook
Linkedin linkedin
Twitter twitter
Google google
Wikidata wikidata

Athersys

us

New York City, US
17 Apr 2024

New York City, US
17 Apr 2024

Athersys

All
News
Images
Maps
Videos
More
Page: 1 Desktop | Laptop Devices

https://www.athersys.com/home/default.aspx
Athersys, Inc.
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human ...
https://www.athersys.com › news-and-media
News & Media
Press Releases ... Athersys Reports Third Quarter 2023 Financial Results and Bu... ... Athersys Extends Near Term Liquidity with Proceeds from Warr... ... Athersys ...
https://www.fiercebiotech.com › biotech › athersys-files...
Athersys files for bankruptcy, sells assets to Healios
Jan 9, 2024 — With Athersys' days now numbered, Healios has swooped in and bought up all of the biotech's assets for $2 million via a credit bid.
https://www.athersys.com › management-team
Our People - Leadership
Maia Hansen, MBA, MS, Chief Operating Officer. Ms. Hansen joined Athersys in 2020 as Senior Vice President of Operations and Supply Chain, and in June 2022 was ...
https://www.biospace.com › article › athersys-adds-to-s...
Athersys Adds to Surge of Biotechs Filing for Bankruptcy, ...
Jan 9, 2024 — Continuing the surge of biotech bankruptcies, Athersys filed for Chapter 11 on January 5, according to an SEC filing. All assets of the ...
https://www.athersys.com › investors
Investors
We have a bold goal – we are working towards changing the future of medicine. Here at Athersys, we have established a portfolio of therapeutic product ...
https://www.linkedin.com/company/athersys
Athersys
We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through ...
https://www.athersys.com › news-and-media › video
News & Media - Video
Related Searches
Related Searches
athersys buyout
athersys careers
athersys news today
Knowledge Panel
Knowledge Panel

Athersys Inc (Biotechnology company)

athersys.com/home/default.aspx

  • Stock price : ATHXQ (OTCMKTS) $0.00 0.00 (-2.44%)Apr 17, 4:00 PM EDT - Disclaimer
  • Founded : 1995
  • Headquarters : Cleveland, OH

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 89788